Interleukin-1 beta (IL-1β) is a central pro-inflammatory cytokine synthesized as an inactive precursor and activated by caspase-1 through the NLRP3 inflammasome. Dysregulated IL-1β signaling drives pathology across a broad spectrum of diseases, including autoimmune disorders, atherosclerosis, metabolic syndrome, and cancer. The mature ~17 kDa cytokine signals through IL-1R1 and IL-1RAcP, activating NF-κB–dependent inflammatory cascades that promote leukocyte recruitment, cytokine production, and vascular inflammation. Clinically, IL-1β is a validated therapeutic target, exemplified by the success of monoclonal antibody therapies such as canakinumab. Catalina’s rigorously validated IL-1β antibodies provide reliable specificity and sensitivity for investigating inflammatory signaling, disease mechanisms, and therapeutic development.